Dosing & Uses
Dosage Forms & Strengths
single use injection
- 20mg/mL (24mg vial)
Stem Cell Transplantation
Indicated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma and non-Hodgkin lymphoma
Initiate treatment after patient has received granulocyte-colony stimulating factor (G-CSF) qDay for 4 days
Recommended dose: 0.24 mg/kg SC qDay; repeat up to 4 consecutive days; not to exceed 40 mg/day
Start treatment approximately 11 hr prior to apheresis initiation
Acute Myeloid Leukemia (Orphan)
Orphan indication sponsor
- Genzyme Corporation; 500 Kendall Street, Cambridge, MA 02142
Renal Impairment
CrCl >50 mL: No dose adjustment necessary
CrCl <50 mL/min: Reduce Dose by 1/3 to 0.16 mg/kg; not to exceed 27 mg/day
Safety and efficacy not established
Adverse Effects
>10%
Diarrhea (37%)
Injection site reaction (34%)
Nausea (34%)
Fatigue (27%)
Headache (22%)
Arthralgia (13%)
Dizziness (11%)
Vomiting (10%)
1-10%
Insomnia (7%)
Flatulence (7%)
Vomiting (10%)
Postmarketing Reports
Immune System Disorders: Anaphylactic reactions, including anaphylactic shock
Abnormal dreams and nightmares
Blood and lymphatic system: Splenomegaly and splenic rupture
Warnings
Contraindications
None listed in the manufacturer's labeling
History of hypersensitivity; anaphylaxis reported
Cautions
Not intended for HSC mobilization and harvest in patients with leukemia
When used in combination with filgrastim tumor cells may be released from the bond marrow and subsequently collected in the leukapheresis product. Effects of potential reinfusion of tumor cells not studied
Dose reduction recommended in patients with moderate-severe renal impairment
Leukocytosis; use in conjunction with G-CSF increases circulating leukocytes as well as HSC populations
Risk of thrombocytopenia; monitor platelet counts in all patients receiving treatment and then undergo apheresis
Risk of splenic enlargement and rupture
Optimal effective dose in patients wighing >175% of ideal body weight not studied
Cases of splenic enlargement and/or rupture reported following administration in conjunction with growth factor G-CSF
Medications that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor
Pregnancy & Lactation
Pregnancy
Limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes
Advise pregnant women of potential risk to fetus
Advise women of reproductive potential to avoid becoming pregnant while receiving treatment
Verify pregnancy status in females of reproductive potential prior to initiating therapy
Contraception
- Therapy can cause embryo-fetal harm when administered to pregnant women; advise females of reproductive potential to use effective contraception during treatment and for one week after final dose
- Males treated with this medication should use effective contraception during treatment and for one week after cessation of treatment
Animal data
- In animal reproduction studies, subcutaneous administration of plerixafor to pregnant rats during organogenesis at doses ten times maximum recommended human doses resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth
Lactation
There are no data on presence of plerixafor in human milk, effect on breastfed child, or the effect on milk production; because of potential serious adverse reactions in breastfed child, advise females that breastfeeding is not recommended during treatment and for one week after final dose
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
A hematopoeitic stem cell mobilizer. Blocks binding of stromal cell-derived factor-1-alpha, found on bone marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4). The inhibition results in the mobilization of progenitor and hematopoietic stem cells from the bone marrow into peripheral blood.
Absorption
Peak Plasma Time: 30-60 min (SC)
Distribution
Protein Bound: 58%
Vd: 0.3 L/kg
Metabolism
None
Elimination
Half-Life: 3-6 hr
Excretion: Urine 70%
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| plerixafor subcutaneous - | 24 mg/1.2 mL (20 mg/mL) vial |  | |
| plerixafor subcutaneous - | 24 mg/1.2 mL (20 mg/mL) vial |  | |
| plerixafor subcutaneous - | 24 mg/1.2 mL (20 mg/mL) vial |  | |
| plerixafor subcutaneous - | 24 mg/1.2 mL (20 mg/mL) vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
plerixafor subcutaneous
PLERIXAFOR - INJECTION
(pler-IX-a-for)
COMMON BRAND NAME(S): Mozobil
USES: Plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. Stem cells, which are found mainly in the bone marrow, turn into red blood cells, white blood cells, and platelets. Plerixafor is used to help stem cells move from the bone marrow to the bloodstream so that the cells can be collected and stored. The stem cells are then infused back into the patient after chemotherapy or radiation.
HOW TO USE: Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Before injecting each dose, clean the injection site with rubbing alcohol. Change the injection site each time to lessen injury under the skin.Inject this medication under the skin as directed by your doctor, usually about 11 hours before the blood filtering procedure. The dosage is based on your medical condition and weight. Your doctor will also direct you to use another medication (G-CSF) to prepare for the procedure. Carefully follow your doctor's instructions on how to use both medications correctly.
SIDE EFFECTS: Diarrhea, nausea, vomiting, gas, dizziness, or pain/redness/swelling at injection site may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: left upper abdominal pain, left shoulder pain, fainting, easy bleeding/bruising.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using plerixafor, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, leukemia.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using plerixafor. Plerixafor may harm an unborn baby. Your doctor should order a pregnancy test before you start this medication. Men and women using this medication should ask about reliable forms of birth control during treatment and for 1 week after the last dose. If you or your partner becomes pregnant, talk to your doctor right away about the risks and benefits of this medication.It is unknown if this medication passes into breast milk. Because of the possible risk to the infant, breastfeeding is not recommended while using this medication and for 1 week after the last dose. Consult your doctor before breastfeeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: fainting, severe dizziness.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as complete blood count) should be done while you are using it. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised October 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
